tbuckley/cabot-search huggingface dataset:
AB0432 High Prevalence of Metabolic Syndrome in South African Sle Patients:
Authors: A.N. Nkabane, I. Okpechi, B. Hodkinson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Against a background of urbanisation and widespread poverty, the prevalence of the metabolic syndrome (MetS) is increasing in South Africa, and atherosclerotic cardiovascular diseases are emerging as a major cause of mortality. Patients with systemic lupus erythematosus (SLE) are at increased risk of the MetS and its complications, but there are no published studies of the prevalence or associations of the MetS amongst sub-Saharan Africans with SLE. <h3>Objectives</h3> To investigate the prevalence and associations of the MetS amongst recent-onset SLE patients. <h3>Methods</h3> A cross-sectional study of baseline features of an inception cohort of recent onset (&lt;5 years9 disease duration) SLE patients. All patients met the SLICC SLE classification criteria and were attending the rheumatology clinic in a state-sector tertiary academic hospital. The MetS was defined by Joint Interim Statement criteria<sup>1</sup>. <h3>Results</h3> Of 90 patients, the mean (SD) age was 36.7 (12.2) yrs, disease duration was 24.7 (22.9) months, 81 (87.8%) were female, and of these 67 (82.7%) were premenopausal. In terms of ethnicity, 70.0% were of mixed ethnic ancestry and 25.6% were Black Africans. Patients were of poor socio-economic status: 31.1% were unemployed, with a mean (SD) schooling of 10.2 (2.6) yrs. The mean (SD) SLEDAI score was 5.9 (3.4), and 94.4% were ANA positive, and 15 (16.7%) had lupus nephritis. The majority of patients were prescribed chloroquine (97.8%) and low dose corticosteroids (67.1%). The mean (SD) BMI was 26.2 (6.8) kg/m<sup>2</sup>, and 53.3% were smokers. The overall prevalence of MetS in this cohort was 33.3%, and increased waist circumference and reduced HDL- C were the most frequently observed features (Table). There was a trend toward more females having MetS (OR 0.2 (95%CI 0.02–1.4, p=0.09), but there was no association between the MetS and age, menopausal status, disease duration, ethnic group nor with SLEDAI score, presence of dsDNA, hypocomplementaemia, or with organ involvement including nephritis. Surprisingly, neither the use of corticosteroid or their dose was associated with MetS. <h3>Conclusions</h3> South Africans with recently diagnosed SLE are at particularly high risk of atherosclerotic cardiovascular disease due to the high prevalence of the MetS and cigarette smoking. This calls for aggressive primary prevention strategies. <h3>References</h3> Alberti KG et al. Circulation 2009 <h3>Disclosure of Interest</h3> None declared
Accurate Detection of the microRNA Transcriptome in a Leukemia Progression Model.
Authors: Florian Kuchenbauer, Ryan Morin, Johann Staaf, Ake Borg, Bob Agiropoulos, Allen Delaney, Thomas Zeng, Helen Mcdonald, Martin Hirst, Carlos Rovira, Marco Marra, R. Keith Humphries
Journal: Blood (2007)
Elevated FABP1 serum levels are associated with poorer survival in acetaminophen‐induced acute liver failure
Authors: Constantine J. Karvellas, Jaime L. Speiser, Mélanie Tremblay, William M. Lee, Christopher F. Rose
Journal: Hepatology (2016)

Acetaminophen (APAP)‐induced acute liver failure (ALF) is associated with significant mortality. Traditional prognostic scores lack sensitivity. Serum liver‐type fatty acid binding protein (FABP1) early (day 1) or late (day 3‐5) levels are associated with 21‐day mortality in the absence of liver transplant. Serum samples from 198 APAP‐ALF patients (nested case–control study with 99 survivors, 99 nonsurvivors) were analyzed by enzyme‐linked immunosorbent assay with clinical data from the US Acute Liver Failure Study Group registry (1998‐2014). APAP‐ALF survivors had significantly lower serum FABP1 levels early (238.6 versus 690.8 ng/mL, P &lt; 0.0001) and late (148.4 versus 612.3 ng/mL, P &lt; 0.0001) compared with nonsurvivors. FABP1 &gt; 350 ng/mL was associated with significantly higher risk of death at early ( P = 0.0004) and late ( P &lt; 0.0001) time points. Increased serum FABP1 early (log FABP1 odds ratio = 1.31, P = 0.027) and late (log FABP1 odds ratio = 1.50, P = 0.005) were associated with significantly increased 21‐day mortality after adjusting for significant covariates (Model for End‐Stage Liver Disease, vasopressor use). Areas under the receiver operating characteristic curve for early and late multivariable models were 0.778 and 0.907, respectively. The area under the receiver operating characteristic curve of the King's College criteria (early, 0.552 alone, 0.711 with FABP1; late, 0.604 alone, 0.797 with FABP1) and the Acute Liver Failure Study Group prognostic index (early, 0.686 alone, 0.766 with FABP1; late, 0.711 alone, 0.815 with FABP1) significantly improved with the addition of FABP1 ( P &lt; 0.002 for all). Conclusion : In patients with APAP‐ALF, FABP1 may have good potential to discriminate survivors from nonsurvivors and may improve models currently used in clinical practice; validation of FABP1 as a clinical prediction tool in APAP‐ALF warrants further investigation. (H epatology 2017;65:938‐949)
Clinical Measurement of Prognostic Immune Signature in Follicular Lymphoma by RT-PCR Based Gene Expression Profiling and Immunohistochemistry Demonstrates Favourable T-Cell and Unfavorable Macrophage Infiltration.
Authors: Richard J. Byers, Ebrahim Sakhinia, Preethi Joseph, Caroline Glennie, Sara McDermott, Judith A. Hoyland, Lia Menasce, John A. Radford, Tim Illidge
Journal: Blood (2007)
TNFα Mediated Facilitating Cell Enhancement of Hematopoietic Stem Cell Function in Vivo and In Vitro Involves Bcl-3.
Authors: Francine Rezzoug, Yiming Huang, Michael K. Tanner, Marcin Wysoczynski, Carrie L. Shannie, Mariusz Z. Ratajczak, Isabelle J. Fugie-Vivier, Suzanne T. Ildstad
Journal: Blood (2004)
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
Authors: F. Pietrantonio, R. Miceli, L. Rimassa, S. Lonardi, G. Aprile, A. Mennitto, F. Marmorino, S. Bozzarelli, L. Antonuzzo, E. Tamburini, F. Morano, D. Rossini, F. Battaglin, M. Baretti, R. Berenato, V. Formica, S. Mosconi, F. Petrelli, M. Ghidini, F. Loupakis, D. Spada, S. Cinieri, G. Beretta, A. Falcone, F. de Braud, C. Cremolini
Journal: Annals of Oncology (2016)
SAT0324 Headaches in Patients with Sle – Clinical Characteristics
Authors: S. Monov, R. Shumnalieva, D. Monova, E. Chamurliiska, R. Rashkov
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> According to different authors central nervous system involvement in SLE called neuropsychiatric SLE (NPSLE) varies widely. One of the manifestations of NPSLE is the headache. Although the latter is not included into the diagnostic criteria, its presence is a sign of disease activity. Lupus headache could presents as: migraine, tension, headache of intracranial hypertension, atypical and relapsing pattern. <h3>Objectives</h3> The objective of our study is to identify and characterize the lupus headache in SLE patients with different clinical characteristics. <h3>Methods</h3> 225 SLE patients were included in the study. They were divided in three groups: group I - 62,28% of the patients, with clinically manifested of neuropsychiatric symptoms, group II – 37,72%, with no clinical manifestations of NPSLE and group III – 25,78%, with incomplete SLE. The presence of lupus headache was diagnosed based on the 1999 ACR classification criteria and other possible causes for it have been excluded (untreated hypertension, infections, treatment regimen, etc.). <h3>Results</h3> Lupus headache was present in 52 (23,11%) of the studied patients. It was more common in the patients with clinically active NPSLE (group I) – in 41 (39,42%) of them. In 24 (58,54%) of them the headache had a tension characteristic and a duration from 10 minutes to 4 days. In 10 (24,39%) of them it had a characteristic of migraine. In the rest of the patients with lupus headache – 7 (17,07%), is was the only symptom in the absence of neurologic abnormalities, and in 2 of them (4,88%) retinal vasculitis has been diagnosed by direct ophthalmoscopy. The use of corticosteroids had good therapeutic effect in 87,80% of cases of lupus headache. In group II there were not patients with lupus headache. Lupus headache was demonstrated in 11 patients (18,97%) patients in group III. Lupus headache was more common in the patients with longer disease duration (p=0,047) or higher levels of matrix metalloproteinase 9 in the serum (p&lt;0,001). <h3>Conclusions</h3> In the majority of the SLE patients the lupus headache has a tension characteristic. The use of corticosteroids has good effect in controlling this disease manifestation. <h3>Disclosure of Interest</h3> None declared
Chemical Library Screening Identifies Novel Inhibitors of Cyclin D2 (CCND2) Transactivation That Selectively Induce Apoptosis in Multiple Myeloma Cells.
Authors: Rodger E. Tiedemann, Xinliang Mao, Chng-Xin Shi, Yuan Xiao Zhang, Stephen Palmer, Craig B. Reeder, Aaron Schimmer, Keith Stewart
Journal: Blood (2006)
Identification of Distinct Cytokine and Chemokine Clusters That Correlate with Outcome In B-Cell Chronic Lymphocytic Leukemia: Implications for Disease Pathogenesis
Authors: Xiao-Jie Yan, Wentian Li, Sophie Yancopoulos, Igor Dozmorov, Michael Centola, Steven L. Allen, Kanti R Rai, Nicholas Chiorazzi, Barbara Sherry
Journal: Blood (2010)
A single femoral component for all total hip replacements performed by a trust? Does this affect early clinical and radiological outcomes?
Authors: J. Ricketts, P. Sherry
Journal: International Journal of Surgery (2016)

Background: Hospitals may be under pressure to implement cost saving strategies regarding prosthesis choice. Thismay involve the use of components which are not the first preference of individual surgeons, or those they have littleexperience with. We aim to examine the effect of standardizing the type of femoral stem used in a single trust, anddetermine whether this is safe practice, particularly in those who have never used this particular stem before.Methods: We report results at 2 years of 151 primary total hip arthroplasties performed using a single femoral stem.Data was split into 2 groups: those in which the operating surgeon was previously using this femoral stem, and thosewho were not. Radiographic outcomes measured were leg length discrepancy, cement mantle grade, and femoral stemalignment. We also report on clinical outcomes, complications, and construct survivability.Results: No significant differences in clinical outcomes were observed. Cement quality was generally worse in thosewith no prior use of this stem. Leg length inequality was greater in those previously using the stem (+1.57mm vs3.83mm), however this did not correlate to clinical outcomes. Alignment was similar between the groups (P=0.464).Conclusion: Our findings suggest that although clinical outcomes are similar at 2 years, radiological differences canbe observed even at this early stage in follow up. Choice of components for arthroplasty should remain surgeon led untillong term follow up studies can prove otherwise.
AB1123-HPR The Role of Psychological Defense Mechanisms and The Level of Subjective Control in The Development of Affective Disorders in Patients with Rheumatoid Arthritis
Authors: M. Ramkhelawon, G. Suleymanova, R. Grekhoff, S. Kharchenko
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To examine the role of psychological defense mechanisms (PDM) and level of subjective control (LSC) in the development of affective disorders in patients with rheumatoid arthritis (RA). <h3>Methods</h3> We observed 28 patients with RA. The average age was 55, 59±8, 76 years and the average duration was – 7, 2±4,3years. The questionnaire “level of subjective control” (LSC) (Bazhin E. F., et al. 1993) was used in the study. Psychological defense mechanisms were studied according to the “index of lifestyle” inventory (IL) (E. B. Klubov et al., 1995). The study of affective disorders was conducted by the “neuroticism and psychopatization” psychological test (L. L. Dmitrieva, 1990). <h3>Results</h3> In women, a high intensity of PDM in the type of “Reactive formation” was seen. And in men, a higher tension in PDM in the type of “Displacement” and “Intellectualization” (p&lt;0.01) was noted. RA patients with the third stage of activity had lowest indices related directly to defense “Denial” (p&lt;0.05). Asthenia, depression, anxiety and hypochondria are directly correlated with the parameters of PDM “Reactive formations” (H). The level of asthenia and anxiety were directly correlated with intensity of “Regression” defense mechanism (r=0,316 and r=0,365; p=0.010 and p=0.003). The level of asthenia and depression were directly correlated with the defense “Projection” (r=0,399 and r=0,343; p=0.001 and p=0.005). Patients with RA were mostly characterized by external locus of control in common sphere (3,81+1,387), failures (3,51+0,64), family relations (4,18+0,55), industrial relations (2,74+0,98), health (4,66+1,94). The general internal locus of control in RA patients was significantly decreased (p=0.006) along with increasing stage of the disease. Significant negative correlations were established between the levels of asthenia, anxiety and hypochondria and internal locus of control (p=-0, 45; p=-0, 52; p=-0, 40, respectively, when r=0,005); and between level of anxiety and internality of failures (p=-0, 42, p=0.05). <h3>Conclusions</h3> The obtained data indicate the passiveness of RA patients fighting with the disease, and failure to appreciate the connection between their actions and important events of their lives; hence in this background, a choice more towards non-adaptive psychological defense mechanisms is made which in turn exacerbates the neurotic reactions in RA patients. <h3>Disclosure of Interest</h3> None declared
THU0493 Racial Disparities in The Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis as Urate-Lowering Drug Adverse Events in The Us
Authors: N. Lu, S. Rai, R. Terkeltaub, S. Kim, M. Menendez, H. Choi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Although uncommon, the most feared adverse event of urate-lowering drugs (ULDs) is allopurinol hypersensitivity syndrome (AHS), primarily manifesting as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). <i>HLA-B*5801</i> allele carriage (a strong determinant of AHS) varies substantially among races, which may lead to major racial disparities in the risk of SJS/TEN in the context of ULD adverse events (ULDAEs). Such information could immediately help risk stratification to prevent these severe ULDAEs. <h3>Objectives</h3> To examine potential racial disparities in the risk of SJS/TEN in the context of ULDAEs in a large, racially diverse, and generalizable population. <h3>Methods</h3> Using the Nationwide Inpatient Sample (NIS, 2009–2013), a database representative of all US hospitalizations, we examined the racial distribution of hospitalized SJS/TEN (principal discharge diagnosis) as ULDAEs (ICD-9-CM Classification of External Causes); this combination implicates allopurinol, which is the only ULD established to cause SJS/TEN. Our reference groups were the US Census population, US allopurinol users (from the NHANES), and ULDAE hospitalizations without SJS/TEN (from the NIS). <h3>Results</h3> We identified 606 patients hospitalized for SJS/TEN as ULDAEs meeting our criteria between 2009–2013 (mean age, 68 years; 44% male). Of these 606 patients, there was a substantial over-representation of Asians (27%) and Blacks (26%), and an under-representation of Whites (29%) and Hispanics (% too-low-to-report), compared with the US Census population (5%, 12%, 67%, and 15%, respectively). The hospitalization rate ratios for SJS/TEN among Asians, Blacks, and Whites were 11.9, 5.0, and 1.0 (referent), respectively. These associations persisted using other national referents (allopurinol users and ULDAE cases without SJS/TEN). <h3>Conclusions</h3> These national data indicate that Asians and Blacks have a substantially higher risk of SJS/TEN as ULDAEs than Whites (or Hispanics), correlating well with corresponding frequencies of <i>HLA-B*5801</i> in the US population (i.e.,7.4%, 4%, 1%, and 1% among Asians, Blacks, and Whites, Hispanics, respectively). As no other ULDs available in the US have been established to cause SJS/TEN, these findings support the use of vigilance in these minorities when considering allopurinol. <h3>Disclosure of Interest</h3> None declared
Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy.
Authors: Irene M. Ghobrial, Jeanette E. Eckel, Alexey A. Leontovich, Michael Timm, Gregory Ahmann, Antje Hoering, Stephen Ziesmer, Miguel Cabanela, Alex Nehme, Philip R. Greipp, Rafael Fonseca, Thomas E. Witzig
Journal: Blood (2004)
AB0816 Gouty Flares and Atherogenic Serum Lipid Profile in Patients with Gout
Authors: M. Radak-Perovic, M. Zlatkovic-Svenda
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Atherogenic serum lipid profile is prevalent in gouty patients.Recently conducted <i>in vitro,in vivo and clinical studies</i> of gout have evidenced proinflammatory effects of LDL-C and antiinflammatory properties of HDL-C (1–3). <h3>Objectives</h3> To investigate if atherogenic serum lipid profile in gouty patients predicts gout activity. <h3>Methods</h3> A total number of 69 patients (97,1% male) were divided into two groups with regard to the frequency of their gouty flares: group 1 (up to 1 flare per year) and group 2 (2 or more flares per year, with the maximum flare number of 20). Logistic regression model was used to identify the set of metabolic items able to predict frequent flares in gout. The following variables were included in the model: total cholesterol level (border set up at 5,2 mmol/L), HDL cholesterol level (1,03 mmol/L for men and 1,3 mmol/L for women), LDL cholesterol level (3,37 mmol/L) triglicerydes (1,68 mmol/L) and serum uric acid (359 mmol/L). The fit of the selected model to the actual outcome was determined with a set of goodness of fit tests. All analyses were carried out using statistical program SPSS 20.0. <h3>Results</h3> Logistic model was acceptable, by showing 74% of correctly predicted cases in a classification table with a cut off value of p=0.5. Hosmer and Lemeshow goodness of fit test was found to be nonsignificant (p=0,881), suggesting that model fit to data well. Two additional goodness-of-fit tests which confirmed those results were Cox and Snell R<sup>2</sup> (p=0,195) and Nagelkerke R<sup>2</sup> (p=0,275). According to the logistic regression model, the only significant predictor of the gouty flares frequency in patients with gout was the high LDL cholesterol level (p=0,008). <h3>Conclusions</h3> More frequent flares in patients with gout were predicted by the higher LDL cholesterol level only. Surprisingly, gouty flares were not predicted by serum uric acid level, as it was commonly thought. HDL cholesterol level, total cholesterol level and level of triglycerides were not found to be the predictors of the frequent gout attacks. <h3>References</h3> Jiang X, Li M, Yang Q, Du L, Du J, Zhou J. Oxidized low density lipoprotein and inflammation in gout patients. Cell Biochem Biophys. 2014;69(1):65–9. Scanu A,et al. High density lipoproteins inhibit urate crystal induced inflammation in mice. Ann Rheum Dis 2015;74:587–594. Xing LJ, et al.Plasma Paraoxonase 1,Oxidised Low Density Lipoprotein and Lipid Peroxidation Levels in Gout Patients.Cell Biochem Biophys 2011;61:481–486. <h3>Disclosure of Interest</h3> None declared
Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors—Preliminary Analysis
Authors: Arun Sasikumar, Ajith Joy, M. R. A. Pillai, Raviteja Nanabala, Muhammed Anees K, P. G. Jayaprakash, Jayaprakash Madhavan, Suresh Nair
Journal: Clinical Nuclear Medicine (2016)

Objective To evaluate the feasibility of using 68Ga PSMA-11 PET/CT for imaging brain lesions and its comparison with 18F-FDG. Methods Ten patients with brain lesions were included in the study. Five patients were treated cases of glioblastoma with suspected recurrence. 18F-FDG and 68Ga PSMA-11 brain scans were done for these patients. Five patients were sent for assessing the nature (primary lesion/metastasis) of space occupying lesion in brain. They underwent whole body 18F-FDG PET/CT scan and a primary site elsewhere in the body was ruled out. Subsequently they underwent 68Ga PSMA-11 brain PET/CT imaging. Target to background ratios (TBR) for the brain lesions were calculated using contralateral cerebellar uptake as background. Results In five treated cases of glioblastoma with suspected recurrence the findings of 68Ga PSMA-11 PET/CT showed good correlation with that of 18F-FDG PET/CT scan. Compared to the 18F-FDG, 68Ga PSMA-11 PET/CT showed better visualization of the recurrent lesion (presence/absence) owing to its significantly high TBR. Among the five cases evaluated for lesion characterization glioma and atypical meningioma patients showed higher SUVmax in the lesion with 68Ga PSMA-11 than with 18F-FDG and converse in cases of lymphoma. TBR was better with 68Ga PSMA PET/CT in all cases. Conclusion 68Ga PSMA-11 PET/CT brain imaging is a potentially useful imaging tool in the evaluation of brain lesions. Absence of physiological uptake of 68Ga PSMA-11 in the normal brain parenchyma results in high TBR values and consequently better visualization of metabolically active disease in brain.
P0367 : Sarcopenia is associated with a reduced survival in patients with hepatocarcinoma undergoing sorafenib treatment
Authors: E. Gigante, G. Antonelli, P. Begini, F. Carbonetti, E. Iannicelli, P. Marchetti, A. Pellicelli, L. Miglioresi, G. Delle Fave, M. Marignani
Journal: Journal of Hepatology (2015)
Disparities in the Prevalence of Diagnosed Diabetes — United States, 1999–2002 and 2011–2014
Authors: Gloria L. Beckles, Chiu-Fang Chou
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

The prevalence of diabetes mellitus has increased rapidly in the United States since the mid-1990s. By 2014, an estimated 29.1 million persons, or 9.3% of the total population, had received a diagnosis of diabetes (1). Recent evidence indicates that the prevalence of diagnosed diabetes among non-Hispanic black (black), Hispanic, and poorly educated adults continues to increase but has leveled off among non-Hispanic whites (whites) and persons with higher education (2). During 2004-2010, CDC reported marked racial/ethnic and socioeconomic position disparities in diabetes prevalence and increases in the magnitude of these disparities over time (3). However, the magnitude and extent of temporal change in socioeconomic position disparities in diagnosed diabetes among racial/ethnic populations are unknown. CDC used data from the National Health Interview Survey (NHIS) for the periods 1999-2002 and 2011-2014 to assess the magnitude of and change in socioeconomic position disparities in the age-standardized prevalence of diagnosed diabetes in the overall population and among blacks, whites, and Hispanics. During each period, significant socioeconomic position disparities existed in the overall population and among the assessed racial/ethnic populations. Disparities in prevalence increased with increasing socioeconomic disadvantage and widened over time among Hispanics and whites but not among blacks. The persistent widening of the socioeconomic position gap in prevalence suggests that interventions to reduce the risk for diabetes might have a different impact according to socioeconomic position.
Marqibo® (vincristine sulfate liposomes injection; VSLI) In the Treatment of Adult Patients with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and RALLY Studies
Authors: Susan O'Brien, Deborah A Thomas, Leonard T Heffner, Wendy Stock, Gerald L. Messerschmidt, Anne Hagey, Steven R. Deitcher, Hagop Kantarjian
Journal: Blood (2010)